Research has revealed that in the case of metabolic dysfunction-associated fatty liver disease (MAFLD), the risk of ...

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...

(Michelle Mullins/for the Daily Southtown) Addy was diagnosed with metastatic hepatocellular carcinoma in July 2021. That ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune ...

Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...

Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...

Adakitug is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Solid Tumor.

Hepatitis delta virus testing in those with chronic hepatitis B is low, and improvements are needed to reduce long-term, ...

—Sobia Laique, MD, of Cleveland Clinic, discusses the multitude of pathways that contribute to hepatocarcinogenesis in MASH, including metabolic derangement, gut microbiota, and more. (3:06 ...